These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 18552823)
1. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823 [TBL] [Abstract][Full Text] [Related]
2. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells. Mehregan DR; Hamzavi I Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068 [TBL] [Abstract][Full Text] [Related]
3. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases. Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332 [TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of HMB45 and negative PRAME expression in halo nevi. Ruby KN; Li Z; Yan S J Cutan Pathol; 2021 Apr; 48(4):519-525. PubMed ID: 33184871 [TBL] [Abstract][Full Text] [Related]
5. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977 [TBL] [Abstract][Full Text] [Related]
7. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors. Garola R; Singh V Pathol Res Pract; 2019 Oct; 215(10):152550. PubMed ID: 31351802 [TBL] [Abstract][Full Text] [Related]
8. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. Bahmad HF; Oh KS; Alexis J J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of benign and malignant melanocytic lesions of the conjunctiva using double-staining. Soon AK; Brownstein S; Tang T; Saleh S; Jiang K; Levac J; Blanco P; Farmer J Can J Ophthalmol; 2019 Dec; 54(6):699-707. PubMed ID: 31836103 [TBL] [Abstract][Full Text] [Related]
10. Proliferative activity of primary cutaneous melanocytic tumours. Kuwata T; Kitagawa M; Kasuga T Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909 [TBL] [Abstract][Full Text] [Related]
11. Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy. Wagner SN; Wagner C; Schultewolter T; Goos M Cancer Immunol Immunother; 1997 Jun; 44(4):239-47. PubMed ID: 9222283 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions. Nielsen PS; Riber-Hansen R; Steiniche T Am J Dermatopathol; 2011 Jun; 33(4):361-70. PubMed ID: 21610457 [TBL] [Abstract][Full Text] [Related]
13. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453 [TBL] [Abstract][Full Text] [Related]
14. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Nasr MR; El-Zammar O Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113 [TBL] [Abstract][Full Text] [Related]
15. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Sundram U; Harvell JD; Rouse RV; Natkunam Y Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225 [TBL] [Abstract][Full Text] [Related]
16. The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas. Uguen A; Uguen M; Guibourg B; Talagas M; Marcorelles P; De Braekeleer M Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):361-367. PubMed ID: 27490764 [TBL] [Abstract][Full Text] [Related]
17. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730 [TBL] [Abstract][Full Text] [Related]
18. Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67. Milman T; Zhang Q; Ang S; Elder D; Ida CM; Salomao DR; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC Hum Pathol; 2020 Sep; 103():107-119. PubMed ID: 32707054 [TBL] [Abstract][Full Text] [Related]
19. PRAME expression in genital melanocytic lesions - Potential diagnostic pitfall of intermediate expression in atypical genital nevi. Ng JKM; Choi PCL; Chow C; Li JJX; To KF Pathol Res Pract; 2024 Aug; 260():155404. PubMed ID: 38878667 [TBL] [Abstract][Full Text] [Related]
20. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]